Evidence map›Paper›PMID 17079431›Full record

ArticleClinical and vaccine immunology : CVI2007

Specificity of the immune response to a modified group B meningococcal polysaccharide conjugate vaccine.

Samuel Moore, Esmé K Farley, Peter C Fusco, Francis Michon

Open access · diamondAbstract read
In one paragraph

Article in Clinical and vaccine immunology : CVI, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Samuel MooreDepartment of Vaccine Research, BioVeris Corporation, 16020 Industrial Drive, Gaithersburg, MD 20877, USA. smoore@bioveris.com
Esmé K Farley
Peter C Fusco
Francis Michon

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Antibodies to a modified group B meningococcal polysaccharide vaccine were examined for antigenic and functional specificities. Bactericidal determinants were investigated by using immunoaffinity columns and competitive inhibition of bactericidal activity in an in vitro killing assay. We conclude that nearly all of the vaccine-induced bactericidal activity is specific for the native polysaccharide.

Indexed as

Antibody SpecificityAnimalsAntibodies, BacterialAntigens, BacterialMiceNeisseria meningitidisPolysaccharides, BacterialVaccines, ConjugateAntibodies, BacterialAntigens, BacterialPolysaccharides, BacterialVaccines, Conjugate

Identifiers

PMID17079431
PMCPMC1797716
OpenAlexW2108281888

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.